Abstract
signal sequence and the mechanism of Gal-3 transport to the cell surface remain poorly 23 understood. Here, using a genome-wide CRISPR/Cas9 forward genetic screen for regulators 24 of Gal-3 cell surface localization we identified genes encoding glycoproteins, enzymes Interestingly, Gal-3 is detected at high levels in cardiac patients where it is used as a 54 marker for cardiovascular disease and heart failure (Jagodzinski et al., 2015; Medvedeva, 55 Berezin, Surkova, Yaranov, & Shchukin, 2016). Similarly, elevated levels of galectin-1 (Gal-56 1) are associated with poor prognosis in many cancers including melanoma, lung, bladder and 57 head cancers (Thijssen, Heusschen, Caers, & Griffioen, 2015) .
58
The mechanism of galectin secretion remains controversial. As mentioned above, 59 galectins lack a signal peptide and do not enter the classical ER/Golgi secretory pathway 60 (Hughes, 1999; Nickel, 2003) and their secretion is not blocked by drugs that inhibit the 61 diffuse in the extracellular medium. For instance, exogenous purified Gal-1, -3 and -8 only 95 bind to the cell surface when N-linked glycosylation pathways are intact and N-linked 96 glycans expressed at the cell surface .
97
To identify key regulators of Gal-3 cell surface localization (the sum of both its 98 secretion and its retention) and clarify the role of glycosylation in either, we performed a 99 genome-wide CRISPR/Cas9 forward genetic screen. The most significantly enriched genes 100 identified in the screen encodes glycoproteins, enzymes involved in N-linked glycan 101 maturation and proteins regulating ER-Golgi trafficking.
102
We focused on the role of two genes identified in the CRISPR screen that encode 103 proteins essential for N-linked glycosylation. When N-linked glycosylation was disrupted the 104 level of Gal-3 on the cell surface decreased. This was not due to a disruption of Gal-3 105 secretion from the cytosol to the extracellular space, as free Gal-3 was detected in the 106 medium. This demonstrates that N-linked glycosylation is not required for secretion of 107 but is essential for cell surface binding. These data support a model where N-linked 108 glycosylation is not required for secretion of Gal-3 to the extracellular space.
109
Furthermore, we tested the role of EVs in Gal-3 secretion but we conclude that they are not 110 involved.
112

Results
113
A genome-wide screen identifies genes required for galectin-3 cell surface localization 114 Due to the limited knowledge about Gal-3 trafficking from the cytosol to the cell 115 surface and its regulation, we set out to identify genes required for cell surface localization of 116 Gal-3. At steady state suspension HeLa cells (sHeLa) express Gal-3 on their surface (figure 117 S1A) and there is a small proportion detectable in the medium (figure S1B). To be found on 118 the outer leaflet of cell surface, Gal-3 must be secreted from the cytosol through an Gal-3.
187
To investigate whether N-linked glycosylation is required for transport of Gal-3 from known to be specifically required for N-linked glycosylation ( figure 1C and 1D ). In the cis-
210
Golgi MGAT1 adds N-acetylglucosamine to the sugar backbone of glycoproteins, initiating 211 complex N-linked glycosylation ( figure 1D ). SLC35A2 acts later in the trans-Golgi,
212
transporting UDP-galactose into the trans-Golgi network for addition onto glycoproteins
213
( figure 1D ).
214
We generated MGAT1 and SLC35A2 CRISPR knockout cell lines using guide RNAs 215 from an independent CRISPR/Cas9 library (Wang et al., 2015) . This provides an additional 216 control for off-target effects as the guide RNAs differed from those used in our original
217
CRISPR screen. Single cell cloning, using FACS, was carried out to obtain knockout clones 
275
Western blotting analysis showed that Gal-3 was secreted by MGAT1 (Lec1) and SLC35A2 similar levels of Gal-3 in the medium after removing EVs at 100,000g, indicating that the 294 majority of the secreted Gal-3 is free and not packaged in vesicles ( figure 5A and B) . Gal-3 is 295 detectable in the 100,000g EV pellet of all cell lines, although the levels were somewhat 296 variable, and there was a small increase in the amount of both actin and Gal-3 detected in the 297 EV pellets from MGAT1 deficient clones ( figure 5A and B) . It is important to note that the 298 EV pellets are 50x concentrated compared to the supernatant samples ( figure 5A and B). To 299 assess the composition of the 100,000g pellet further, we analysed the tetraspanin CD63 300 which is known to be enriched in exosomes (Escola et al., 1998) . The 100,000g pellet was it is difficult to comment on the relative levels of CD63 in the EV pellets of the MGAT1 and 306 SLC35A2 compared to the wild type controls. However, we believe that the lack of MGAT1 307 or SLC35A2 does not affect the formation or level of EVs.
308
We also assessed whether Gal-3 secreted from CHO MGAT1 (Lec1), SLC35A2 provide an excellent system for assessing whether extracellular Gal-3 is packaged into EVs.
400
Using differential centrifugation, we show that the vast majority of Gal-3 detected in the 401 medium is free and soluble, indicating Gal-3 is not packaged into extracellular vesicles.
402
These data support an EV independent pathway for Gal-3 trafficking to the cell surface and 403 secretion into the extracellular space.
404
It has previously been shown that Gal-3 is redistributed from the cytosol to mapped to an index of all of the sgRNA sequences in the GeCKO v2 library using Bowtie 2.
512
The resulting sgRNA count tables were then analyzed using the RSA algorithm using the 513 default settings (Rivest, Shamir, & Adleman, 1978) . 0.1% Bromophenol Blue, 10% Glycerol and 100 mM DTT) and boiled at 100˚C for 5 min.
573
Cell pellets were lysed in lysis buffer (20 mM Tris-HCl pH 6.8, 137 mM NaCl, 1 mM EDTA,
574
1% Triton X-100 and 10% Glycerol) at 4˚C for 10 min, insoluble material removed by 575 centrifugation at 10,000 g for 10 min 4˚C. Sample buffer was added and cell lysate were 
Removal of extracellular vesicles
583 Cells were processed as described for the secretion assay except after the 3,000g 584 centrifugation step the medium was collected and centrifuged at 100,000g for 60 min at 4˚C.
585
After each centrifugation step a sample of the medium was collected for western blotting.
586
The extracellular vesicle pellet was resuspended in a small volume of non-reducing sample 587 buffer (50 mM Tris-HCl pH 6.8, 2% SDS (w/v), 0.1% Bromophenol Blue, and 10%
588
Glycerol). Half of the EV pellet sample was taken and DTT added to achieve a final 589 concentration of 100 mM. All samples were boiled and resolved by SDS-PAGE. The entire 590 concentrated EV pellet sample was loaded on two gels (reduced and non-reduced) for each 591 sample due to the small scale of the assay. Therefore the EV pellet is 50x more concentrated 592 than the equivalent supernatant.
594
Statistical analysis
595
Significance levels for comparisons between groups were determined with a two sample
596
Students t-test. 
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The authors declare no competing financial interests. blots to illustrate the large increase in Gal-3 in the supernatant compared to actin.
827
Quantification for MGAT1 (right; green) and SLC35A2 (left; orange) is shown at the bottom.
828
Error bars represent ±s.e.m. from biological replicates (n = 3); * p<0.05 using a two sample
829
Students t-test comparing each cell line to wild type cells. 
833
A. Gal-3 cell surface localization is decreased in MGAT1 and SLC35A2 mutant CHO lines. h. The cells were collected and lysed whereas the medium was subjected to differential 862 centrifugation at 300g, 3000g and 100,000g. A sample of the medium was collected after 863 each centrifugation step. Gal-3 was assessed in the lysate, the entire 100,000g EV pellet and 864 medium (supernatant). Actin was used as a loading control and control for cell lysis.
865
Exposure times are indicated for comparison. The 100,000g EV pellets were also analysed by 866 western blot for levels of glycosylated and non-glycosylated CD63. and actin were analysed by western blot and exposure times are indicated for comparison.
875
CD63 was not analysed in this experiment as it does not cross-react with hamster CD63. expressing GFP-Gal-3 and mRFP-LC3 for 24 h were treated with 1 mM LLOMe for 3 h.
887
Cells were fixed with methanol and processed to confocal microscopy. Bars: 10 um. genome-wide CRISPR screen for Gal-3 cell surface localisation.
